
A new study says that breast tumors can regress when an abundant growth-promoting protein is blocked.
The study is published on March 19th in the Journal of Experimental Medicine.
Advertisement
Triple-negative breast tumors lack all of the known growth receptors that serve as treatment targets in other types of breast cancer, making this the most clinically challenging subtype of the disease. Patients with these tumors tend to relapse earlier and have shorter disease-free survival.
Andrei Goga and colleagues now show that triple-negative breast tumors express elevated levels of the growth-driving protein called MYC. MYC activity was required for the growth of these aggressive tumors, and blocking a MYC-cooperating protein, CDK, caused triple-negative tumors to shrink in mice.
Together, these results identify a potential new target for triple-negative tumor treatment.
Source: Eurekalert
Together, these results identify a potential new target for triple-negative tumor treatment.
Source: Eurekalert
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News

The mechanism by which the kinases cause inflammation has been discovered by scientists.

Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.

New combination of medications trametinib and entinostat were found to decrease lung cancer in mice.

Combination treatment with TALZENNA and XTANDI was found to benefit prostate cancer patients, revealed study.

In leukemia patients, reduced amounts of dietary vitamin A is associated with a higher risk and severity of pancreatitis.